AZTEC

Trial Acronym	AZTEC
Trial Title	AZacitidine Treatment Effect on Hypertrophic Cardiomyopathy
Clinical Area	Symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM)
Trial Status	Set Up
Trial Registration

 

 

---

• Recruitment

  Recruitment Target	24 (Phase 2a) 48 (Phase 2b)
  Date Open to Recruitment
  Date Closed to Recruitment

• Trial Design

  Trial Design	An open-label dose escalation Phase 2a trial followed by a randomised, controlled, open-label Phase 2b efficacy trial
  Study Aim	Evaluate the safety and efficacy of azacitidine in patients with symptomatic nHCM

• Chief Investigator (CI)

  Chief Investigator

  Dr Lana Dixon, Belfast Health & Social Care Trust lana.dixon@belfasttrust.hscni.net

• Sponsor(s) & Funder(s)

  Sponsor	Belfast Health and Social Care Trust
  Funder(s)	British Heart Foundation, Innovate UK and The Heart Trust Fund